Close Menu

New Products

Jan 14, 2020

Genome Diagnostics NGSengine

Genome Diagnostics has released a new version of its NGSengine human leukocyte antigen typing software. The updated NGSengine is now capable of exporting HLA typing results of individual samples directly to the Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) matching-services website, thanks to a recent partnership between Netherlands-based GenDx and German firm PIRCHE. This, the company said, will give laboratories the ability to predict indirectly recognizable HLA epitopes for either hematopoietic stem cells or solid organs.

Jan 13, 2020

Bio-Rad Laboratories SEQuoia

Bio-Rad Laboratories announced the launch of the SEQuoia Complete Stranded RNA Library Prep Kit for RNA-Seq library preparation. The kit uses SEQzyme, an enzyme that couples cDNA synthesis with adapter addition in a continuous synthesis reaction. It is compatible with a broad range of sample inputs and allows capture of the complete transcriptome, including short and long RNAs, in a single library prep. The kit generates cDNA libraries suitable for strand-specific next-generation sequencing on Illumina sequencers in less than four hours. It also includes access to the integrated SeqSense analysis solution to process and quality control sequencing data for all RNA biotypes in the library within a single analysis pipeline.

Jan 13, 2020

OncoCyte DetermaRx

OncoCyte has launched the DetermaRx, test for identifying early-stage lung cancer patients who may benefit from adjuvant chemotherapy after surgical resection. The test was formerly known as the Razor treatment stratification test and was being developed by Razor Genomics, which OncoCyte acquired in September. Regulators in Canada have approved the test for marketing in that country, the Irvine, California-based firm said. In the US, Florida Precision Oncology and the Leonard Cancer Institute at Mission Hospital in Mission Viejo, California have signed up as early access users of the test, OncoCyte said. It said that in a clinical study, high-risk patients identified by the test post-surgery and treated with adjuvant chemotherapy had a "significant" increase in survival rates. 

Jan 13, 2020

Dovetail Genomics: Genome Assembly Services With Omni-C

Dovetail Genomics has launched an expanded menu of genome assembly services, including 3D genome conformation analysis, annotations, and chromosome-scale assemblies.

The services leverage the firm's Omni-C technology, which provides improved scaffolding, SNP detection, and haplotype phasing.

Jan 09, 2020

Qiagen QiaSymphony PowerFecal Pro DNA Kit

Qiagen has launched the QiaSymphony PowerFecal Pro DNA Kit for the isolation of microbial genomic DNA from stool and soil using the QiaSymphony automation platform. The new kit enables automated, time-saving, standardized extraction of inhibitor-free DNA from stool and soil samples for metagenomic analysis, and is designed for 192 samples with continuous loading of 24-sample batches. Qiagen said that its new PowerBead Pro tubes are included in the kit for homogenization. The beads and optimized chemistry enable more efficient lysis of bacteria and fungi.

Jan 09, 2020

Pillar Biosciences Onco/Reveal Solid Tumor Panel

Pillar Biosciences has launched the Pillar Onco/Reveal Solid Tumor Panel, a 47-gene enrichment assay for research use. The panel leverages Pillar's SLIMamp enrichment chemistry, which uses primers that are designed to form stem loops to suppress unwanted amplicons during PCR amplification, enabling multiplexed NGS library preparation in a single tube. The test was licensed from Columbia University and recently received approval from the New York State Department of Health.

Jan 09, 2020

Personalis NeXT Dx Test

Personalis has launchedthe NeXT Dx Test, a next-generation sequencing panel designed to help oncologists identify potential therapies and clinical trial options for cancer patients. The assay analyzes approximately 20,000 genes in both the tumor exome and transcriptome, and includes advanced analytics to provide a diagnostic report on genetic alterations in medically important cancer genes, as well as emerging immunotherapy-related biomarkers such as microsatellite instability status and tumor mutational burden.

Jan 08, 2020

Viracor Eurofins 'Viracor TRAC'

Viracor Eurofins has begun offering its Viracor TRAC donor-derived, cell-free DNA assay for diagnosing kidney transplant rejection. The noninvasive liquid biopsy test has similar characteristics to other donor-derived cfDNA assays on the market, Viracor Eurofins said. Two ongoing prospective and one retrospective clinical trials are underway to further develop clinical data to support use of the test. The current gold standard for diagnosing kidney transplant rejection and surveillance is organ biopsy, which is both expensive and can lead to multiple complications for the patient, the firm noted. 

Jan 07, 2020

PreventionGenetics Rapid PGxome WES Test

PreventionGenetics has added the Rapid PGxome whole-exome sequencing test to its clinical testing menu. It is ideal for situations where a rapid genetic diagnosis is essential, including patients with neonatal, infantile,  or early childhood onset severe disorders, the company noted. Rapid PGxome starts at $2,290 per test and must be ordered by a qualified healthcare provider. It has a turnaround time of 14 days and, in cases with a clear positive result, a preliminary report may be issued in as few as six days.

Jan 06, 2020

Sysmex Ipsogen JAK2 DX

Sysmex has launched the ipsogen JAK2 DX reagent after the product received health insurance coverage in Japan on Jan. 1. The Kobe, Japan-based firm said that it received marketing approval for the gene testing kit that measures the JAK2V617F mutation quantitatively in December 2018. The test is used to diagnose certain hematopoietic tumors, specifically polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Sysmex inked a distribution deal with Ipsogen (now part of Qiagen) in 2011 covering Japan that allows Sysmex to distribute some Ipsogen blood cancer products in that country.

Jan 02, 2020

AMS Biotechnology cfPure Max Cell-Free DNA Purification Kit

AMS Biotechnology has released the cfPure Max kit for circulating cell-free DNA purification. It is designed for samples with a volume of at least 5 ml. The company's cfPure kits use silica-coated paramagnetic particles to purify cell-free DNA from less than 1 ml to more than 10 ml of serum or plasma, for downstream applications such as bisulfite sequencing, next-generation sequencing, or qPCR.

Dec 19, 2019

Lucid Diagnostics EsoGuard Esophageal DNA Test

PAVmed's Lucid Diagnostics subsidiary has launched its EsoGuard Esophageal DNA Test as a laboratory-developed test after completing CLIA/CAP certification of the test. EsoGuard is a DNA test designed to facilitate the diagnosis of Barrett's esophagus and related precursors to esophageal adenocarcinoma.

EsoGuard LDT is performed on cells which are noninvasively sampled from the distal esophageal lining and shipped in a custom preservative solution to the ResearchDx facility in Irvine, California, where the DNA is immediately extracted. The DNA is then subjected to bisulfite conversion, PCR amplification, and next-generation sequencing to determine the methylation status of 31 sites on the vimentin and cyclinA1 genes, the company said. A bioinformatic algorithm is used to calculate the percentage of DNA molecules in which a proportion of methylated sites on either gene exceeds a certain threshold, delivering a positive or negative result.

A positive result has been associated with the presence of non-dysplastic Barrett's esophagus, dysplastic Barrett's esophagus, or esophageal adenocarcinoma, PAVmed added.

Dec 16, 2019

SpeeDx ResistancePlus MG FleXible

SpeeDx has launched the ResistancePlus MG FleXible for the GeneXpert System in Europe. The test detects Mycoplasma genitalium and markers associated with azithromycin resistance. It is now available in France and the UK, to be followed by the rest of the EU, Australia, and New Zealand. Cepheid is the exclusive distribution partner of the test through its FleXible Cartridge program for the GeneXpert System.

Dec 16, 2019

BioIVT NGS Services

BioIVT has launched next-generation sequencing services. The services include target mutation and subject cohort identification, human tissue procurement, sample and library preparation, sequencing, bioinformatics, and project design and management. The firm is offering both standard and custom services for assay validation as well as exploratory research.

Dec 12, 2019

Caris Life Sciences MI GPS Score

Caris Life Sciences has launched the MI GPS (Genomic Profiling Similarity) Score, an AI-driven tumor type biology similarity score that uses more than 6,500 mathematical models in the machine learning algorithm to compare molecular characteristics of a patient's tumor against Caris' extensive database. The results are intended to provide new insights into the molecular subtype of cancer of unknown primary (CUP) cases, atypical clinical presentation cases, and other difficult-to-treat cancer cases to help guide treatment decisions, the company said.

Dec 12, 2019

Qlucore Omics Explorer V3.6

Qlucore has released version 3.6 of its Qlucore Omics Explorer (QOE) data analysis software. QOE provides fast, simple, visual analysis of measured data from a wide range of sources and instruments. It ships in a base module with an option to add a module with extensive functionality for next-generation sequencing data analysis. The program integrates well with workflows and through the Python-based template functionality it is possible to control the program through a script and to configure well-defined analysis steps. V3.6 has several new features including the direct import of single-cell data and improved survival calculations using hazard ratios; the addition of one more classifier method (gradient-boosted decision trees) in the machine learning module; and an expanded suite of standard templates, including templates for direct import of single-cell data from 10x Genomics and one for direct download from The Cancer Genome Atlas.

Dec 12, 2019

Fluxion Biosciences Spotlight Liquid Biopsy NGS Panels

Fluxion Biosciences has launched three new targeted next-generation sequencing liquid biopsy panels, including Spotlight Myeloid, Spotlight EGFR, and the Spotlight TP53. The Alameda, California-based firm's Spotlight Myeloid panel includes 478 amplicons that cover 23 clinically relevant genes implicated in acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms. The Spotlight EGFR panel offers contiguous coverage of EGFR and hotspot coverage of BRAF, KRAS, and NRAS mutations, using a 17-amplicon design to generate multiplex libraries compatible with Illumina sequencing platforms. The Spotlight TP53 panel uses 21 amplicons with an average size of 140 base pairs, providing coverage of all TP53 coding regions. According to Flux Bio, the panels have been validated and come with its ERASE-Seq variant caller

Dec 12, 2019

Cergentis TLA Technology

Cergentis has launched its Target Locus Amplification (TLA) technology for sequencing complete cancer genes. TLA relies on DNA crosslinking and has advantages for analyzing DNA from FFPE tumor samples, according to the company, which is based in Utrecht, the Netherlands. It analyzes both single nucleotide variants and structural variants.

Dec 10, 2019

Fluidigm Maxpar Antibodies

Fluidigm has released more than 100 pathologist-verified Maxpar antibodies for use with imaging mass cytometry on the Hyperion Imaging System. The company's portfolio now includes antibodies verified for use with both formalin-fixed, paraffin-embedded and frozen tissues. Imaging mass cytometry provides visualization of complex cellular phenotypes and their relationships in the context of cancer, immuno-oncology, and immune-mediated diseases. Using the dual capability of the Hyperion Imaging System, researchers can deeply profile a wide range of samples from blood to tissues using both mass cytometry and imaging mass cytometry, Fluidigm said.

Dec 10, 2019

Bionano Genomics Prep SP Bone Marrow Aspirate Kit

Bionano Genomics has launched a new kit for DNA isolation from bone marrow aspirates.

The Bionano Prep SP Bone Marrow Aspirate Kit allows for the consistent isolation of ultra high molecular weight DNA in four hours. Bone marrow aspirates, the primary sample type collected from leukemia patients, are traditionally considered a more complex sample type, due to cell clumps and other insoluble impurities.

Dec 10, 2019

GenScript Precision Mutant Library Services

GenScript has launched Precision Mutant Library Services for the drug development, industrial chemical, and synthetic biology markets. The new service utilizes GenScript's proprietary semiconductor oligo synthesis technology to deliver precise control over each synthesized variant. The result is a more diverse and fully covered mutant library with unbiased distribution.

The Precision Mutant Library Services include site-saturation mutagenesis, saturation scanning mutagenesis, or combinatorial mutagenesis libraries. Saturation mutagenesis libraries provide the ability to screen mutations located at several sites within a protein sequence or across the total sequence space. Each position is mutated to all 19 non-wild-type amino acids. Combinatorial mutagenesis libraries involve mutating multiple positions simultaneously across specific target regions of a protein and exploring all possible combinations of mutations.

Dec 10, 2019

Horizon Discovery Predesigned Synthetic sgRNAs

Horizon Discovery is now offering predesigned synthetic single guide RNA (sgRNA). The sgRNAs are available individually or as library collections, and are being offered as an expansion to the company's Edit-R gene engineering platform. Using synthetic sgRNAs enables researchers to achieve reliable gene knockouts, even in complex, difficult-to-edit cell types and experimental models, Horizon said. The synthetic sgRNAs have been designed to maximize the likelihood of functionally knocking out the gene or genes of interest while minimizing off-target effects.

When paired with Cas9 mRNA or Cas9 protein, the sgRNAs also allow researchers to perform DNA-free gene editing in a new one-part format, streamlining their gene editing workflows without the potential for nuclease or guide integration into the cell's genome. They can also be paired with expressed formats such as Cas9 integrated cell lines.

Dec 05, 2019

InterVenn Biosciences OpenPIP Mass Spectrometry Analysis Software

InterVenn Biosciences has made its proprietary mass spectrometry analysis software available for public use. Powered by artificial intelligence and machine learning, OpenPIP reduces the time and cost of integrating and quantifying mass spec data while increasing the quality of output by eliminating observer-based bias. The software is accessed via the Google Cloud Platform and has demonstrated greater than 99 percent concordance with human peak selection, the company said. A publication detailing the specific neural network architecture is currently undergoing peer review. 

Dec 05, 2019

Dante Labs: Whole GenomeH

Dante Labs has launched Whole GenomeH, a next-generation sequencing-based testing service featuring genome assembly with both long and short read technologies.

The test, which costs $1,999, uses both Illumina NovaSeq and Oxford Nanopore Technologies PromethIon sequencing systems.

Dec 04, 2019

Macrogen: Northeast Asia Reference Database

Macrogen of Korea has released the Northeast Asian Reference Database (NARD). It includes whole-genome sequencing and genetic variant data for a panel of 1,779 individuals, including 850 Koreans, 384 Mongolians, 396 Japanese, 91 Chinese, and 58 Hong Kong residents, making it the largest reference panel representing those countries, according to the company. Macrogen expects the database will help improve the accuracy of imputation in genome-wide association studies and predict disease based on polygenic risk scores. Early next year, the company plans to release a second reference panel, from 10,000 individuals.

Pages

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.